Immatics N.V. (IMTX) stock
IMTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.10−0.19 (-3.02%)
Close on Nov 18, 2026Market cap $817.84MP/E –Yield –
Immatics net income
Net income is the profit left for shareholders after every expense, interest and tax.
For fiscal 2023 it was -€94.65M, down 441.7% from the year before. The highest annual figure on record is €27.70M in fiscal 2022.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -€94.65M | -441.7% |
| FY2022 | Dec 31, 2022 | €27.70M | – |
| FY2021 | Dec 31, 2021 | -€93.34M | – |
| FY2020 | Dec 31, 2020 | -€211.28M | – |
| FY2019 | Dec 31, 2019 | -€31.57M | – |
| FY2018 | Dec 31, 2018 | -€31.44M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2024 | Sep 30, 2024 | -€5.31M | – |
| Q2 FY2024 | Jun 30, 2024 | -€17.99M | – |
| Q1 FY2024 | Mar 31, 2024 | -€2.24M | – |
| Q2 FY2021 | Jun 30, 2021 | -€26.53M | – |
| Q2 FY2020 | Jun 30, 2020 | -€21.04M | – |
See a number that looks wrong?